Significance of serum amyloid a on the prognosis in patients with renal cell carcinoma

Kimura, Michio; Tomita, Yoshihiko; Imai, Tomoyuki; Saito, Toshihiro; Katagiri, Atsuko; Ohara-Mikami, Yukie; Matsudo, Takayuki; Takahashi, Kota

doi:10.1002/1097-0142(20011015)92:8<2072::aid-cncr1547>3.0.co;2-p

Cited by 73 publications

(51 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In chronic inflammation, however, which plays a critical role in tumor development, SAA levels increase substantially and indeed also increase in a number of neoplastic diseases. It has been observed in previous studies that the SAA level increases in patients with stomach, lung, renal, colorectal, breast and other forms of cancers (Biran et al, 1986;Glojnaric et al, 2001;Kimura et al, 2001;O'Hanlon et al, 2002;Cho et al, 2004;Chan et al, 2007;Farooqui et al, 2012). With regard to HCC, only one research confirmed the relation of circulating SAA with HCC, and verified a gradual increase of SAA levels in serum from normal to HBV and then to HCC, but cannot be regarded as a specific indicator for assessing HBV and HCC.…”

Section: Discussionmentioning

confidence: 95%

“…Moreover, recent epidemiologic studies even suggest that elevated circulating levels of SAA, not only merely mark the presence of prevalent carcinoma, but also should possibly be related to an increased risk of future cancer in apparently healthy individuals (Sasazuki et al, 2010;Shiels et al, 2013). Most importantly, several researches have confirmed that SAA turned out to be an independent and effective factor in predicting survival of patients with different tumors (Kimura et al, 2001;Chan et al, 2007;Meng et al, 2014).…”

Section: Serum Amyloid a Is A Novel Prognostic Biomarker In Hepatocelmentioning

confidence: 96%

“…Serum SAA levels were increased in patients with lung cancer (Nel et al, 1984;Benson et al, 1986;Khan et al, 2004), prostate cancer (Kaneti et al, 1984), colorectal carcinoma (Glojnaric et al, 2001;Giessen et al, 2014) and renal cell carcinoma (Kimura et al, 2001;Mittal et al, 2012). In addition, a number of previous studies proposed a direct correlation between SAA concentrations and tumor stage that a higher percent of raised SAA levels was found in patients with more advanced disease (Weinstein et al, 1984;Biran et al, 1986;Chen et al, 2007;Liu et al, 2007).…”

Section: Serum Amyloid a Is A Novel Prognostic Biomarker In Hepatocelmentioning

confidence: 99%

See 2 more Smart Citations

Serum Amyloid A is a Novel Prognostic Biomarker in Hepatocellular Carcinoma

Ni¹,

Ye²,

Fu³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Purpose: To investigate the prognostic value of serum amyloid A (SAA) in patients with hepatocellular carcinoma (HCC) undergoing surgery. Materials and Methods: Preoperative serum samples of 328 patients with HCC who underwent curative resection and of 47 patients with benign liver lesion were assayed. Serum levels of SAA were measured by enzyme-linked immunosorbent assay and its correlations with clinicopathological characteristics and survival were explored. Results: Levels of SAA were significantly higher in patients with HCC than those with benign liver lesion. There were strong correlations between preoperative serum SAA level and tumor size and more advanced BCLC stage. On univariate analysis, elevated SAA was associated with reduced disease-free survival and overall survival (p=0.001 and 0.03, respectively). Multivariate analyses showed that serum SAA level was an independent prognostic factor for overall survival (hazard ratio 2.80, p=0.01). Conclusions: High SAA serum level is a novel biomarker for the prognosis of HCC patients.

show abstract

Section: Discussionmentioning

confidence: 95%

Section: Serum Amyloid a Is A Novel Prognostic Biomarker In Hepatocelmentioning

confidence: 96%

Section: Serum Amyloid a Is A Novel Prognostic Biomarker In Hepatocelmentioning

confidence: 99%

See 1 more Smart Citation

Serum Amyloid A is a Novel Prognostic Biomarker in Hepatocellular Carcinoma

Ni¹,

Ye²,

Fu³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…HP is a well characterized APP with increasing evidence as a cancer biomarker [21][22][23][24][25]. Lastly, SAA is an acute phase apolipoprotein associated as a marker of cancer progression [26][27][28][29][30]. In NB, Combaret et al identified high SAA levels were detected in patient sera with poor prognosis [31].…”

Section: Resultsmentioning

confidence: 99%

Serum Protein Profiling to Identify High-Risk Neuroblastoma: Preclinical Relevance of Blood-Based Biomarkers

Sandoval

Turner

Hoelz

et al. 2007

Journal of Surgical Research

View full text Add to dashboard Cite

Introduction-Development of early detection assays for advanced stage neuroblastoma (NB) remains elusive. We have previously shown serum protein profiling technologies can differentiate healthy from NB children. As various sources of patient related bias exist in serum proteins, we hypothesized a well controlled animal model may provide a better method to identify tumor bloodbased markers during NB progression.

show abstract

“…Although our microarrray experiments identified significantly increased expression of IL-8 in aggressive primary and metastatic CCRCC, this differential expression was marginally significant (P < 0.055) by our quantitative RT-PCR experiments. Another gene, serum amyloid A, has been identified in the serum of CCRCC patients, and elevated serum levels are associated with aggressive CCRCC (25). Serum amyloid A1 and A2 are acute-phase reactants whose expression is regulated in part by IL-1 and IL-6 (26 -28).…”

Section: Discussionmentioning

confidence: 99%

Clear Cell Renal Cell Carcinoma: Gene Expression Analyses Identify a Potential Signature for Tumor Aggressiveness

Kosari¹,

Parker

Kube³

et al. 2005

Clinical Cancer Research

140

View full text Add to dashboard Cite

Purpose: The objective of this study was to use gene expression profiling to identify novel biomarkers that are predictive of aggressive behavior in clear cell renal cell carcinoma (CCRCC). Experimental Design: Candidate genes were discovered using Human Genome U133 Plus 2 Arrays and validated on independent samples by quantitative reverse transcription-PCR (RT-PCR). Both the discovery and the validation cohorts included nonaggressive primary CCRCC, aggressive primary CCRCC, metastatic CCRCC, and nonneoplastic kidney adjacent to tumor. Results: Aggressive primary and metastatic CCRCC displayed no significant differences in gene expression. In contrast, we identified significant differences in gene expression between nonaggressive andaggressive CCRCC (including metastatic CCRCC).Thirty-fourof the 35 transcriptsthat displayed the most significant differential expression by microarray analysis also displayed significant differential expression inindependent validation studies using quantitative RT-PCR (P < 0.001 for 31candidates and P < 0.005 for the remaining three candidates). Hierarchical clustering of the quantitative RT-PCR data using our candidate markers accurately grouped 88% (23 of 26) of aggressive and metastatic CCRCC samples, 100% (14 of 14) of nonaggressive CCRCC samples, and100% (15 of15) of nonneoplastic samples into separate clusters. Finally, we evaluated theability of protein expression levels of one of our candidate markers (survivin) to predict survival among a cohort of 183 CCRCC patients treated surgically at Mayo Clinic from 1990 to 1992. In multivariate analysis, expression of survivin (BIRC5) was inversely associated with cancer-specific survival (P = 0.017). Conclusion: We used a combination of genomic profiling and validation by quantitative PCR to identify a panel of candidate biomarkers for determining CCRCC aggressiveness. Our data also indicate that the gene expression alterations that result in aggressive behavior and metastatic potential can be identified in the primary tumor.

show abstract

Significance of serum amyloid a on the prognosis in patients with renal cell carcinoma

Cited by 73 publications

References 9 publications

Serum Amyloid A is a Novel Prognostic Biomarker in Hepatocellular Carcinoma

Serum Amyloid A is a Novel Prognostic Biomarker in Hepatocellular Carcinoma

Serum Protein Profiling to Identify High-Risk Neuroblastoma: Preclinical Relevance of Blood-Based Biomarkers

Clear Cell Renal Cell Carcinoma: Gene Expression Analyses Identify a Potential Signature for Tumor Aggressiveness

Contact Info

Product

Resources

About